

Virtual Travel Clinic

Pharmacy Partnership Overview

Preventive travel-health infrastructure for pharmacy partners.

virtualtravelclinic.ca

The size of Canada's travel-health opportunity -- and how a pharmacy captures it without building the clinical operation itself.

Visual Executive Summary

EXECUTIVE SUMMARY

Capture the travel-health patient — without building the clinic.

You have the patients. We have the clinical capacity. VTC completes the travel consultation and returns the prescriptions to your pharmacy — you keep the patient, the prescriptions, and the relationship.

THE OPPORTUNITY

13.0M

overseas trips by Canadians, 2024

▲ 31% vs 2023

Many are headed somewhere that warrants vaccines, antimalarials, and preventive advice — a list topped by Mexico.



Only about half of travellers to higher-risk destinations get any pre-travel advice — the rest leaks to a family doctor, a website, or nowhere.

THE MODEL

1 · Book

2 · ISTM consult, MD-overseen

3 · Rx returned to pharmacy

4 · Patient fills & stays

No clinical workload at the store — just a QR code or booking link.

THE ECONOMICS · PER ACTIVE LOCATION, PER YEAR

Consultations 1,200

Patients 1,820

Prescriptions 6,720

5.6 Rx per consultation · 3.7 Rx per patient

\$355,000

gross travel-prescription revenue
per location · per year

Scales directly with every active store.

VTC brings its own demand

Partner-sourced

VTC-sourced — net-new

THE NEXT STEP

A bounded pilot, measured store by store — proof that belongs to you, not a claim from us.

Book a 20-minute walkthrough — virtualtravelclinic.ca

Confidential — prepared by Virtual Travel Clinic for discussion purposes.
Sources: Statistics Canada (2024); travel-medicine literature; CIHI (2023); VTC operating data.

Executive Summary

You have the patients. We have the clinical capacity. Virtual Travel Clinic completes the travel consultation and sends the prescriptions back to your pharmacy -- so you capture the travel-health customer without building, staffing, or licensing a travel clinic of your own.

The division of labour is simple: **you don't build or operate a travel clinic -- VTC does the clinical work.** A patient you refer completes an ISTM-certified travel consultation with us, **the prescriptions are returned to your pharmacy, and the customer stays yours.** VTC supplies the entire certified clinical operation as turnkey infrastructure; you supply the counter and the relationship.

- **The opportunity** -- Canadians took 13.0 million overseas trips in 2024, a meaningful share to destinations that warrant vaccines, antimalarials, and preventive advice -- yet only about half of travellers to less-developed countries obtain any pre-travel advice. That intent leaks today to a family doctor, a website, or nowhere at all.
- **The model** -- A patient is referred to VTC, completes an ISTM-certified travel consultation with physician oversight, and the prescriptions are returned to the referring pharmacy for fulfillment. No clinical workload is added at the store -- just a QR code or booking link.
- **The economics** -- At annualized run-rate, an active location generates roughly 1,200 consultations, 1,820 patients, and 6,720 prescriptions a year -- about \$355,000 in gross travel-prescription revenue per active location per year, scaling directly with active store count. VTC also generates its own demand, routing new travel-health patients into the network rather than only monetizing existing foot traffic.
- **The next step** -- A bounded pilot in a defined set of stores, with store-level tracking so the prescription impact is measured directly -- proof that belongs to you, not a claim from us.

Bottom line: the pre-travel moment is among the cheapest ways to acquire a premium, repeat household -- and VTC makes it operational at the locations where the foot traffic already is.

The travel-health customer

A pharmacy evaluating travel health usually measures it as a service line -- so many consultations, so many scripts, a margin per visit. That understates what is on the table.

A pre-travel interaction is a **patient-acquisition event**, and the patient it acquires is unusually valuable: affluent, travelling as a household, travelling repeatedly, and arriving already intending to spend on health. The question worth costing is not “*what does one travel consult earn?*” It is “*what is a travel-health customer worth to this pharmacy over time?*”

A large, growing, higher-risk travel market

International travel by Canadians is large, growing, and recurring -- and a meaningful share is headed somewhere that warrants vaccines, antimalarials, and preventive advice.

- Canadians made **13.0 million overseas trips** (beyond the United States) in 2024 -- a post-pandemic high, up roughly 31% from 2023 and above 2019 levels for the first time. (Statistics Canada)
- Across all international travel, they took 38.7 million trips abroad and spent **\$52.9 billion**, averaging about **\$2,300 per overseas trip** over roughly 13 nights. (Statistics Canada, National Travel Survey)
- Mexico is the most-visited overseas destination, followed by sun destinations such as the **Dominican Republic**; **China** and **India** are significant for visiting friends and relatives -- precisely the destinations that call for pre-travel preparation. (Statistics Canada)
- 67% of Canadians hold a passport, and they travel internationally for leisure at roughly **twice the per-capita rate of Americans**. (Destinations International)

The customers pharmacies want

Three traits make this segment worth acquiring well beyond the value of a single visit.

Trait	Why it matters to a pharmacy
Affluent	Canadian travellers earning over \$200K spend 38% more on international trips than the average traveller; globally, affluent households drive roughly one in four travel dollars. (Destinations International; Visa)
Households, not individuals	Family vacations are the most popular type of international leisure trip -- so one pre-travel interaction frequently brings a spouse, children, and travel companions into the pharmacy together. (Destinations International)
Repeat	Higher-income travellers take about 4.3 leisure trips a year. International travel is a habit, not a one-off -- the acquisition recurs. (Resonance Consultancy)

A travel-health touchpoint is, in effect, a low-cost door to a high-income, multi-person, repeat-visit relationship.

Demand that already exists -- and is largely unmet

The need is real and common; what is missing is reliable preparation -- which is exactly the gap a pharmacy is positioned to close.

- Travellers' diarrhoea is the most predictable travel illness, with attack rates of **30–70% over a two-week trip** to higher-risk destinations -- a list that includes Mexico, the Dominican Republic, and most of Latin America, Africa, and South and Southeast Asia. (CDC Yellow Book)
- Yet only about **half of travellers** to less-developed countries obtain any pre-travel advice; in airport surveys only ~35% got it from a health professional, and just **~12% received a pre-travel vaccine**. (travel-medicine literature)
- Roughly **half of travellers report a health problem** during their trip. The need is real, common, and largely unmet. (GeoSentinel surveillance network)

The pharmacy that owns the pre-travel moment is not manufacturing demand -- it is capturing intent that today leaks to a family doctor, a website, or nowhere at all.

From one trip to a lifetime

The value compounds across four tiers. Most analyses stop at the first; the real prize sits in the last two.

Tier	What it captures	Why it compounds
1 -- The trip	Vaccines, antimalarials, travellers' diarrhoea kit, repellent, OTC, pre-trip refills	The immediate basket
2 -- The household	Spouse, children, travelling companions	Multiplies the basket per trip
3 -- The year	Multiple international trips annually	Recurring, not one-time
4 -- The relationship	Ongoing prescriptions and front-store visits	The bulk of lifetime value

An illustrative lifetime value

Canadians spend, on average, more than \$1,000 per person per year on prescription drugs (\$42.1 billion across roughly 41 million people). Converting a travelling household into a retained pharmacy relationship is therefore worth, on a public-average basis:

Input (illustrative)	Value	Basis
Prescription spend per person, per year	~\$1,000	\$42.1B ÷ ~41M (CIHI, 2023)
Household size	4	Family travel most common
Retention horizon	5–10 years	Illustrative
Prescription throughput per household	~\$20,000–\$40,000	Calculated
+ Per-trip travel-health basket	Additive	Per trip, per member
+ Front-store / OTC on every visit	Additive	55% of Canadians visit weekly

***Illustrative and top-line.** Figures show prescription throughput, not pharmacy margin -- a partner captures dispensing and markup economics on that volume plus full front-store margin, and should substitute its own retention, basket, and margin assumptions. Because this segment skews affluent and ages over the retention window (per-person fills rise from ~5.4 a year at ages 18–24 to ~8.3 at 65+), these public averages are likely conservative for travel-health customers.*

And the relationship anchors into the highest-frequency touchpoint in Canadian healthcare:

- Canada's prescribed-drug spend reached **\$42.1 billion in 2023**; public spending alone hit \$20.1 billion in 2024 and is growing about 9% a year. (CIHI)
- **55% of Canadians visit a community pharmacy weekly** and see a pharmacist up to ten times more often than their family doctor. (Canadian Pharmacists Association)
- Per-person prescription use rises steadily with age, so a household's value **grows over the years it is retained**. (Canada Health Infoway)

The strategic implication is straightforward: the pre-travel moment is among the cheapest, highest-intent ways for a pharmacy to acquire a premium, multi-person, repeat household -- provided the pharmacy can reliably deliver the clinical side of travel medicine at the locations where the foot traffic already is. That is what Virtual Travel Clinic provides.

What Virtual Travel Clinic is

Virtual Travel Clinic (VTC) is best understood as preventive travel-health infrastructure -- a national clinical capability that can be embedded into an existing pharmacy and patient journey, without a pharmacy partner having to build, staff, license, and maintain the clinical operation itself.

The infrastructure already exists on our side: virtual travel-medicine consultations, certified travel-medicine clinicians, physician oversight, prescribing workflows, patient support, compliance, and national operating capacity. The partner supplies fulfillment and the local patient relationship; VTC supplies the certified clinical layer behind it.

A pharmacy-connected pathway

The opportunity is not simply to offer travel consults. It is to give patients a clear, pharmacy-connected pathway when they need travel-health advice, vaccine planning, or travel-related prescriptions -- while keeping the operational lift low at the store level.

In practice, many locations are already fielding these questions from travelling patients, but without a simple national pathway to support them consistently. VTC provides that pathway.

How it works

The patient journey is consistent end to end:

1. The patient is referred to VTC.
2. The patient completes an ISTM-certified travel consultation, based on the planned itinerary and personal health history, with travel-medicine physician oversight.
3. The prescriptions are returned to the referring pharmacy.
4. The patient fills the prescriptions and becomes -- or remains -- the pharmacy's customer.

The patient is acquired, prepared, and returned to the referring pharmacy.

Fulfillment, vaccines, and the local relationship remain with the partner -- the model keeps the patient, it does not send them away.

Per active location -- annualized run-rate

The figures below reflect a single active location's annualized run-rate, once the referral pathway is established.

Metric	Per year
Travel consultations completed per location	1,200
Patients served	1,820
Prescriptions generated	6,720
Average Rx per patient	3.7
Average Rx per consultation / group	5.6

Travel medicine is high-yield per visit. A single consultation often covers a family or travelling group, so prescriptions generated typically exceed the number of consultations -- an average of **5.6 prescriptions per consultation**.

At an estimated gross revenue of roughly **\$195 per travel patient** (inclusive of a flat \$20 injection fee), this volume represents approximately **\$355,000 in gross travel-prescription revenue per active location** per year -- and it scales directly with the number of stores actively participating.

That \$355,000 is travel-prescription revenue only -- the first of three revenue streams a retained travel-health customer opens: (1) travel-health prescriptions, the run-rate above; (2) ongoing, non-travel prescriptions once the customer stays with the pharmacy; and (3) front-store and non-prescription purchases on each visit. Streams (2) and (3) are not included in the run-rate; their compounding value is set out in *From one trip to a lifetime* above.

VTC brings its own demand

Prescription volume is produced through two channels:

- **Partner-sourced** -- patients referred at the counter, via in-store QR codes, or booking links.
- **VTC-sourced** -- patients who found VTC independently through paid and organic search, content, travel agents, tour operators, and family-physician referrals, and chose the partner pharmacy for fulfillment.

The second channel matters: VTC does not simply monetize existing pharmacy foot traffic. It generates demand and routes new travel-health patients into the partner network.

Why it matters to a pharmacy chain

Travel medicine naturally creates prescription and vaccine volume -- but the model does not depend on pharmacists becoming a sales force. The stronger opportunity is to capture travel-health intent that already exists and route those patients through a reliable clinical pathway.

- **Incremental prescription and vaccine volume** -- the primary, measurable benefit, and one of the key drivers of overall pharmacy performance.
- **Ancillary retail** -- travel patients frequently purchase complementary items in the same visit (sunscreen, insect repellent, first-aid, passport photos, currency, luggage).
- **Loyalty and retention** -- keeps travel customers from churning to standalone travel clinics or competing pharmacies, positioning the partner as the destination for all of their travel-health needs.

Clinical credibility

VTC is built to give a pharmacy partner full clinical confidence:

- Care delivered to ISTM-aligned travel-medicine standards, with travel-medicine physician oversight.
- Registered nurses with 100+ hours of travel-specific training.
- Capability for Yellow Fever and complex travel-medicine cases.
- Canadian-owned, with no offshore call centres.

Virtual Travel Clinic is operated by Rockdoc, a Canadian healthcare services company established in 2008.

Low-friction implementation

The lift at the store level is intentionally light. VTC provides:

- Refreshed in-store promotional materials and signage.
- Pharmacy-manager and staff briefings on the referral pathway.
- A simple handoff -- a QR code or booking link, with no clinical workload added at the store.
- Store-level performance reporting and visibility.
- A Customer Success team to support managers and patients by phone.

Suggested next step

The lowest-risk way to evaluate the model is a bounded pilot in a defined set of stores, with store-level tracking so the prescription impact is measured directly -- proof that belongs to you, not a claim from us.

VTC supports activation throughout; the partner's role is simply ensuring the referral pathway is understood and used at participating locations.

As a next step, we would welcome a short Zoom meeting to assess fit -- a chance to walk through the model, answer your questions, and determine together whether a pilot makes sense for your network.

Sources

Market figures in the opening section are drawn from public and industry sources; the run-rate and per-unit economics are Virtual Travel Clinic's own operating data. Two Statistics Canada programs are cited (the National Travel Survey, a household survey, and Travel Between Canada and Other Countries / Frontier Counts, a border-crossing count); they use different methods and are not added together.

1. Overseas trips (13.0M, 2024; +31% YoY; first time above 2019). *Statistics Canada*, "Travel between Canada and other countries, December 2024" (*The Daily*, Feb 2025).
2. Trips abroad (38.7M), international travel spend (\$52.9B), ~\$2,300 per overseas trip, top destinations. *Statistics Canada*, *National Travel Survey, Q1–Q4 2024* (*The Daily*).
3. Passport ownership (67%); per-capita international leisure travel vs. U.S.; affluent travellers (>\$200K) spend 38% more. *Destinations International*, "Five Ways to Woo More Canadian Travelers."
4. Affluent households drive ~25% of travel spend; ~4.3 leisure trips/year among higher-income travellers. *Visa Business & Economic Insights* (2025); *Resonance Consultancy*, reported in *Travel Market Report* (2026).
5. Travellers' diarrhoea attack rate (30–70%) and high-risk destination list. *CDC Yellow Book: Health Information for International Travel*, "Travelers' Diarrhea."
6. ~50% of travellers seek pre-travel advice; ~35% from a health professional; ~12% vaccinated; ~50% report illness while travelling. *Peer-reviewed travel-medicine literature* (PMC/NIH reviews; *BMC Public Health* airport survey; *GeoSentinel* surveillance network).
7. Prescribed-drug spend (\$42.1B, 2023); public spend (\$20.1B, 2024, +9.3%); per-capita derivation. *Canadian Institute for Health Information (CIHI)*; *PMPRB/NPDUIIS*; *National Health Expenditure Trends 2024*.
8. Prescriptions per person by age (~5.4 at 18–24 to ~8.3 at 65+, among those prescribed medication). *Canada Health Infoway* (via *Statista*).
9. 55% of Canadians visit a pharmacy weekly; pharmacist visit frequency vs. physician. *Canadian Pharmacists Association*; *Canadian Pharmacists Journal* (2020).